TRANSFORMING GROWTH FACTOR BETA-1 IN HUMAN COLORECTAL CANCER PATIENTs

Yıl 2011, Cilt: 8 Sayı: 1, 53 - 56, 01.03.2011

Ahu Sarbay Kemik Ozgür Kemik Mine Adas İsmail Hasırcı Ahmet Cumhur Dulger Sevim Purisa Sefa Tuzun

https://izlik.org/JA27NT94TP

Öz

Anahtar Kelimeler

-

TRANSFORMING GROWTH FACTOR BETA-1 IN HUMAN COLORECTAL CANCER PATIENTs

https://izlik.org/JA27NT94TP

Öz

-

Anahtar Kelimeler

-

Kaynakça

• Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor beta. Growth factors 1993; 8: 1-9.
• Massague J. TGFβ signaling: receptors, transducers, and mad proteins. Cell 1996; 85: 947-950.
• Geiser AG, Busam KJ, Kim SJ, et al. regulation of the transforming growth factor-beta1 and beta3 promotes by transcription factor Sp1. Gene 1993; 129: 223-228.
• Grande JP. Role of the transforming growth factor beta in tissue injury and repair. PSEBM 1997; 214: 27-40.
• Wineselt MP, Ramsey GW, Barnard JA. Type II TGF-beta receptor expression in intestinal cell lines and intestinal tract. Carcinogenesis 1996; 67: 573-579.
• Landström M, Eklöv S, Colosetti P, et al. Estrogen induces apoptosis in a rat prostatic adenocarcinoma. Association with an increased expression of TGF beta1 and its type-1 and type-II receptors. Int J cancer 1996; 67: 573-579.
• Sun LZ, Wu G, Wilson JKV, et al. Expression of transform- ing growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994; 269: 26449-26455.
• Kim WS, Park C, Jung YS, et al. Reduced transforming growth factor beta type II receptor expression in adeno- carcinoma of the lung. Anticancer Res 1999, 19. 301-306.
• Lawrance DA. Latent-TGF-beta: an overview. Mol Cell Biochem 2001;219:163-70.
• Hill Rp, Rodemann HP, Hendry JH, Roberts SA, Anscher MS. Normal tissue radiobiology: from the laboratory to the clinic. Int J Radiat Oncol Biol Phys 2001;49:353-65.
• Wu SP, Theodorescu D, Kerbel RS, Willson JK, Mulder KM, Humphrey LE, Brattain MG. TGF-beta 1 is an autocrine- negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector. J Cell Biol 1992;116:187-96.
• Friedman E, Gold LI, Klimstra D, Zeng ZS, Winawer S, Cohen A. High levels of transforming growth factor beta 1 correlate with disease progression in human colon can- cer. Cancer Epidemiol Biomarkers Prev 1995; 4: 549-554.
• Angenete E, Langenskiöld M, Palmgren I, Falk P, Öresland T, Ivarsson ML. Transforming growth factor beta-1 in rec- tal tumor, mucosa and plasma in relation to radiothera- py and clinical outcome in rectal cancer patients. Int J Colorectal Dis 2007;22:1331-8.
• Narai S, Watanabe M, Hasegawa H, Nishibori H, Endo T, Kubota T, Kitajima M. Significance of transforming growth factor beta 1 as a new tumor marker for colorectal can- cer. Int J Cancer 2002;97:508-11.
• Tsamandas AC, Kardamakis D, Ravazoula P, Zolota V, Salakou S, et al. The potential role of TGF beta1, TGF beta2 and TGF beta3 protein expression in colorectal car- cinomas. Correlation with classic histopathologic factors and patient survival. Strahlenther Onkol 2004;180:201-8.
• Kushiyama Y, Fukuda R, Suetsugu H, et al. Site-dependent production of transforming growth factor beta-1 in colon- ic mucosa: its possible role in tumorigenesis of the colon. J Lab Clin Med 2000; 136: 201-8.
• Tsushima H, Kawata S, tamura S, Ito N, Shirai Y, Kiso S, Imai Y, et al. High levels of transforming growth factor beta1 in patients with colorectal cancer: association with disease progression. Gastroenterology 1996; 110: 375-82.
• Shim KS, Kim KH, Han WS, Park EB. Elevated serum lev- els of transforming growth factor beta1 in patients with colorectal cancer: its association with tumor progression and its significant decrease after curative surgical resec- tion. Cancer 1999; 85: 554-61.